Sunshine Biopharma, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SBFM research report →
Companywww.sunshinebiopharma.com
Sunshine Biopharma, Inc. , a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; and SBFM-PL4, an anti-coronavirus treatment compound.
- CEO
- Steve N. Slilaty
- IPO
- 2022
- Employees
- 52
- HQ
- Pointe-Claire, QC, CA
Price Chart
Valuation
- Market Cap
- $1.84M
- P/E
- -0.30
- P/S
- 0.05
- P/B
- 0.08
- EV/EBITDA
- 0.76
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 32.49%
- Op Margin
- -12.90%
- Net Margin
- -17.01%
- ROE
- -25.58%
- ROIC
- -20.57%
Growth & Income
- Revenue
- $36.31M · 4.11%
- Net Income
- $-5,975,352 · -16.39%
- EPS
- $-1.44 · 80.33%
- Op Income
- $-4,478,782
- FCF YoY
- 62.93%
Performance & Tape
- 52W High
- $2.43
- 52W Low
- $0.28
- 50D MA
- $0.99
- 200D MA
- $1.32
- Beta
- 1.49
- Avg Volume
- 7.92M
Get TickerSpark's AI analysis on SBFM
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 14, 26 | NATAN DAVID | other | 100,000 |
| Jan 13, 25 | Roy Michel | other | 0 |
| Mar 4, 24 | Slilaty Steve N. | buy | 100,000 |
| Feb 8, 24 | Slilaty Steve N. | buy | 20,000 |
| Jan 26, 24 | Beaudoin Marc | other | 0 |
| Nov 30, 22 | Sebaaly Camille | buy | 30,000 |
| Oct 20, 22 | Chamoun Malek | other | 0 |
| Jun 3, 22 | Sebaaly Camille | buy | 25,000 |
| Feb 18, 22 | Slilaty Steve N. | sell | 990,000 |
| Feb 10, 22 | NATAN DAVID | other | 0 |
Our SBFM Coverage
We haven't published any research on SBFM yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate SBFM Report →